Skip to main content

Phibro Animal Health Corporation (PAHC) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $55.04 (+3.50%)

Consensus Target
$49.00
Upside
-11.0%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $49.00High $49.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Apr 15, 2025Erin WrightMorgan Stanley$20.00-63.7%

PAHC vs Sector & Market

MetricPAHCHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1818
Target Upside-11.0%+1150.3%+14.9%
P/E Ratio24.466.8531.19

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$385M$386M$388M3
2026-09-30$404M$407M$410M1
2026-12-31$416M$419M$422M2
2027-03-31$428M$431M$434M1
2027-06-30$440M$444M$446M2
2028-06-30$1.60B$1.60B$1.60B4

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$0.68$0.72$0.783
2026-09-30$0.80$0.81$0.821
2026-12-31$0.92$0.93$0.941
2027-03-31$0.76$0.77$0.781
2027-06-30$0.68$0.69$0.701
2028-06-30$3.71$3.75$3.781

Frequently Asked Questions

What is the analyst consensus for PAHC?

The consensus among 1 analysts covering Phibro Animal Health Corporation (PAHC) is Buy with an average price target of $49.00.

What is the highest price target for PAHC?

The highest price target for PAHC is $20.00, set by Erin Wright at Morgan Stanley on 2025-04-15.

What is the lowest price target for PAHC?

The lowest price target for PAHC is $20.00, set by Erin Wright at Morgan Stanley on 2025-04-15.

How many analysts cover PAHC?

1 analysts have issued ratings for Phibro Animal Health Corporation in the past 12 months.

Is PAHC a buy or sell right now?

Based on 1 analyst ratings, PAHC has a consensus rating of Buy (2.00/5) with a -11.0% upside to the consensus target of $49.00.

What are the earnings estimates for PAHC?

Analysts estimate PAHC will report EPS of $0.72 for the period ending 2026-06-30, with revenue estimated at $386M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.